Literature DB >> 24692325

Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study.

Francisco J de Abajo1, Miguel J Gil, Patricia García Poza, Verónica Bryant, Belén Oliva, Julia Timoner, Luis A García-Rodríguez.   

Abstract

PURPOSE: The purpose of this study is to estimate the risk of nonfatal acute myocardial infarction (AMI) associated with traditional NSAIDs (tNSAIDs), non-narcotic analgesics (paracetamol and metamizole), and symptomatic slow-acting drugs in osteoarthritis (SYSADOAs) overall and in different subgroups of patients.
METHODS: We performed a nested case-control study using a Primary Care Database (Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria), over the study period, 2001-2007. We included patients aged 40-90 years, with nonfatal AMI and randomly selected controls matched for age, sex and calendar year. Exposure to drugs was assessed within a 30-day window before the index date.
RESULTS: We did not find an association with nonfatal AMI in patients at low-intermediate background cardiovascular risk (odds ratio = 0.92; 95% confidence interval: 0.76-1.12), whereas there was a moderate significant association among those at high risk (1.28; 1.06-1.54) or when tNSAIDs were used for longer than 365 days (1.43; 1.12-1.82). The greatest risk occurred when these two conditions were combined (1.80; 1.26-2.58). The risk varied across individual tNSAIDs, with ibuprofen (0.95; 0.78-1.16) in the lower and aceclofenac (1.59; 1.15-2.19) in the upper part of the range. Low-dose aspirin did not modify the risk profile showed by any of the individual tNSAIDs examined. Paracetamol (0.84; 0.74-0.95), metamizole (1.06; 0.87-1.29) and SYSADOAs (0.68; 0.47-0.99) were not associated with an increased risk overall or in any subgroup of patients.
CONCLUSIONS: The risk of nonfatal AMI varied with individual tNSAIDs, duration of treatment and background cardiovascular risk. Paracetamol, metamizole and SYSADOAs did not increase the risk in any of the conditions examined.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  NSAIDs; adverse drug reaction; analgesics; myocardial infarction; osteoarthritis; paracetamol; pharmacoepidemiology

Mesh:

Substances:

Year:  2014        PMID: 24692325     DOI: 10.1002/pds.3617

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  20 in total

1.  Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity.

Authors:  Pedro Melgar-Lesmes; Fernando Garcia-Polite; Paula Del-Rey-Puech; Elisabet Rosas; Juliana L Dreyfuss; Eulàlia Montell; Josep Vergés; Elazer R Edelman; Mercedes Balcells
Journal:  Atherosclerosis       Date:  2015-12-13       Impact factor: 5.162

2.  Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study.

Authors:  Francesco Lapi; Carlo Piccinni; Monica Simonetti; Miriam Levi; Pierangelo Lora Aprile; Iacopo Cricelli; Claudio Cricelli; Andrea Fanelli
Journal:  Intern Emerg Med       Date:  2015-08-14       Impact factor: 3.397

3.  Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.

Authors:  Mai Duong; Abdelilah Abouelfath; Regis Lassalle; Cécile Droz; Patrick Blin; Nicholas Moore
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

4.  Differential effects of antidepressant subgroups on risk of acute myocardial infarction: A nested case-control study.

Authors:  Rasha Alqdwah-Fattouh; Sara Rodríguez-Martín; Francisco J de Abajo; Diana González-Bermejo; Miguel Gil; Alberto García-Lledó; Francisco Bolúmar
Journal:  Br J Clin Pharmacol       Date:  2020-05-09       Impact factor: 4.335

5.  Chondroitin Sulphate Attenuates Atherosclerosis in ApoE Knockout Mice Involving Cellular Regulation of the Inflammatory Response.

Authors:  Pedro Melgar-Lesmes; Alvaro Sánchez-Herrero; Ferran Lozano-Juan; Jose María de la Torre Hernández; Eulàlia Montell; Wladimiro Jiménez; Elazer R Edelman; Mercedes Balcells
Journal:  Thromb Haemost       Date:  2018-06-06       Impact factor: 5.249

6.  Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study.

Authors:  Matthias Huber; Frank Andersohn; Giselle Sarganas; Elisabeth Bronder; Andreas Klimpel; Michael Thomae; Christine Konzen; Reinhold Kreutz; Edeltraut Garbe
Journal:  Eur J Clin Pharmacol       Date:  2014-11-08       Impact factor: 2.953

Review 7.  [Perioperative analgesia with nonopioid analgesics : Joint interdisciplinary consensus-based recommendations of the German Pain Society, the German Society of Anaesthesiology and Intensive Care Medicine and the German Society of Surgery].

Authors:  Ulrike M Stamer; Joachim Erlenwein; Stephan M Freys; Thomas Stammschulte; Dirk Stichtenoth; Stefan Wirz
Journal:  Anaesthesist       Date:  2021-07-19       Impact factor: 1.041

Review 8.  Osteoarthritis year in review 2015: clinical.

Authors:  L Sharma
Journal:  Osteoarthritis Cartilage       Date:  2016-01       Impact factor: 6.576

Review 9.  [Perioperative analgesia with nonopioid analgesics : Joint interdisciplinary consensus-based recommendations of the German Pain Society, the German Society of Anaesthesiology and Intensive Care Medicine and the German Society of Surgery].

Authors:  Ulrike M Stamer; Joachim Erlenwein; Stephan M Freys; Thomas Stammschulte; Dirk Stichtenoth; Stefan Wirz
Journal:  Chirurg       Date:  2021-05-26       Impact factor: 0.955

Review 10.  [Perioperative analgesia with nonopioid analgesics : Joint interdisciplinary consensus-based recommendations of the German Pain Society, the German Society of Anaesthesiology and Intensive Care Medicine and the German Society of Surgery].

Authors:  Ulrike M Stamer; Joachim Erlenwein; Stephan M Freys; Thomas Stammschulte; Dirk Stichtenoth; Stefan Wirz
Journal:  Schmerz       Date:  2021-08       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.